CURACLE
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · 51-200 Employees
View Company Info for Free
Overview
Website
www.curacle.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CURACLE
CURACLE (KOSDAQ) is a Korea-based clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics for the treatment of aged-related vascular and intractable metabolic diseases and cancers. Founded in 2016, CURACLE has developed the disease-expressive screening system, SOLVADYS Platform, which screens substances that directly convert the pathological characteristics of the capillary vessels such as leakage, inflammatory activation, and apoptosis using human organ-specific primary endothelial cells. The SOLVADYS Platform dramatically improves the efficacy and ease of administration for acute and chronic conditions that are accompanied by vascular leakage, inflammation and loss of endothelial cells.Explore more
Popular SearchesCURACLE CoCURACLE Co LtdSIC Code 28,283NAICS Code 32,325Show moreCURACLE Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CURACLE your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if CURACLE is spiking on competitors!
Check if CURACLE has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on CURACLE recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at CURACLE
Funding: Get notified immidiatlly once CURACLE has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when CURACLE launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
CURACLE, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if CURACLE had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
CURACLE is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CURACLE is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CURACLE.
CURACLE Tech Stack
A closer look at the technologies used by CURACLE
See more technologies
CURACLE News & Media
CURACLE y Théa anuncian un acuerdo de licencia y colaboración para el desarrollo y comercialización de un tratamiento de administración oral para el edema macular diabético y la degeneración macular exudativa asociada a la edad
SEÚL, Corea del Sur--(BUSINESS WIRE)--CURACLE, una empresa biofarmacéutica coreana, ha anunciado hoy que ha firmado un acuerdo exclusivo de licencia y colaboración con Théa Open Innovation (TOI), la empresa asociada de Théa, la compañía oftalmológica independiente número uno de Europa con 150 años de historia, para el desarrollo y la comercialización de CU06-RE de CURACLE, que tiene el potencial de convertirse en el primer tratamiento administrado por vía oral para el edema macular diabético yCURACLE et Théa annoncent un accord de licence et de collaboration pour le développement et la commercialisation d'un traitement administré par voie orale pour l'œdème maculaire diabétique et la DMLA humide
SÉOUL, Corée du Sud--(BUSINESS WIRE)--CURACLE, une société biopharmaceutique basée en Corée, a annoncé aujourd'hui avoir conclu avec Théa Open Innovation, la société sœur de Théa, le numéro un européen de l'ophtalmologie indépendante fort de 150 ans d’histoire, un accord exclusif de licence et de collaboration pour le développement et la commercialisation du CU06-RE de CURACLE, qui a le potentiel de devenir le premier traitement administré par voie orale pour l'œdème maculaire diabétique et laCURACLE und Théa geben Lizenzierungs- und Kooperationsvereinbarung für die Entwicklung und Vermarktung einer oral verabreichten Behandlung des diabetischen Makulaödems und der feuchten AMD bekannt
SEOUL, Südkorea--(BUSINESS WIRE)--CURACLE, ein in Korea ansässiges biopharmazeutisches Unternehmen, gab heute die Unterzeichnung einer exklusiven Lizenz- und Kooperationsvereinbarung mit Théa Open Innovation bekannt, dem Schwesterunternehmen von Théa, Europas führendem unabhängigen Unternehmen für Augenheilkunde mit einer 150-jährigen Geschichte, für die Entwicklung und Vermarktung von CU06-RE von CURACLE mit dem Potenzial, die erste oral verabreichte Behandlung für diabetisches Makulaödem undCURACLE e Théa annunciano un accordo di licenza e collaborazione per lo sviluppo e la commercializzazione di un trattamento a somministrazione orale per l’edema maculare diabetico e la degenerazione maculare senile essudativa
SEUL, Corea del Sud--(BUSINESS WIRE)--CURACLE, una società biofarmaceutica coreana, ha annunciato quest’oggi di aver concluso un accordo di licenza e collaborazione esclusivo con Théa Open Innovation, la società sorella di Théa, azienda di oftalmologia indipendente numero uno in Europa che vanta 150 anni di storia, finalizzato allo sviluppo e alla commercializzazione di CU06-RE di CURACLE, che potenzialmente potrà diventare il primo trattamento a somministrazione orale per l’edema maculare diab
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CURACLE
Sign Up For FreeTo access detailed company insights
CURACLE (KOSDAQ) is a Korea-based clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics for the treatment of aged-related vascular and intractable metabolic diseases and cancers. Founded in 2016, CURACLE has developed the disease-expressive screening system, SOLVADYS Platfor... Read More
